Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 28 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
10 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
UCB BIOPHARMA from Anderlecht, company number BE0543573053, closed financial year 2025 with a result of € 113.8 million after tax. For that financial year UCB BIOPHARMA recorded revenue of € 3.6 billion and equity of € 1.2 billion. Compared with financial year 2024, the result moved from € 8.5 million to € 113.8 million. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.
€ 1.2 billion
▲ 7% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 113.8 million
▲ € 105.3 million vs 2024
Profit after tax over the fiscal year.
€ 153.8 million
▲ € 127.9 million vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 157.3 million.
People and assets in 2025
1,395.2
▲ 77.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 400.8 million
▲ 11% vs 2024
€ 287,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 9.8 million
▲ 75% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 4.3 billion
▲ 27% vs 2024
Loans from banks and other lenders, long and short.
€ 871.9 million
▼ 17% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 106 days on average.
€ 75 million
▲ 11% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 2,850,940,162 | € 2,617,131,393 | € 3,560,535,341 | € 3,642,138,046 | ▲ 2% |
| Profit after taxes | € -519,501,153 | € -676,933,225 | € 8,462,666 | € 113,811,131 | ▲ € 105.3 million |
| Equity | € 970,331,232 | € 293,398,007 | € 1,101,860,673 | € 1,175,020,354 | ▲ 7% |
| Total debts | € 4,046,826,501 | € 4,531,441,169 | € 4,787,153,902 | € 5,609,060,553 | ▲ 17% |
| Cash | € 87,406,203 | € 87,146,179 | € 25,879,024 | € 153,763,016 | ▲ € 127.9 million |
| Land & buildings | - | - | - | € 226,690 | |
| Retained profit | € -1,824,637,800 | € -2,501,571,025 | € 8,462,666 | € 157,304,538 | ▲ € 148.8 million |
| Bank debt | € 2,780,980,363 | € 3,383,051,148 | € 3,416,853,218 | € 4,331,014,123 | ▲ 27% |
| Balance sheet total | € 5,305,267,743 | € 5,133,880,523 | € 6,244,745,945 | € 7,153,115,798 | ▲ 15% |
| Employees (FTE) | 1,267.9 | 1,269.4 | 1,317.9 | 1,395.2 | ▲ 77.3 |
Key figures of UCB BIOPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to UCB BIOPHARMA?
What happened at UCB BIOPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 113.8 million (▲ € 105.3 million vs 2024). Source: NBB ↗
- Alistair HENRY became a director. NBB
- Denelle J. WAYNICK JOHNSON became a director. NBB
- New establishment in Leuven. KBO
- Sandrine DUFOUR became a director. NBB
- Jean-Luc FLEURIAL became a director. NBB
- New establishment in Braine-l'Alleud. KBO
- New establishment in Anderlecht. KBO
In short
From € 519.5 million loss in 2022 to € 113.8 million profit in 2025.
Paid € 10.6 million in corporate taxes since 2022.
Best year ever: 2025, with € 113.8 million profit.
Pays suppliers within 106 days on average.
A new publication or filing at UCB BIOPHARMA? We notify you, reason included.
Follow UCB BIOPHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind UCB BIOPHARMA are Sandrine DUFOUR, Jean-Luc FLEURIAL, Alistair HENRY and Denelle J. WAYNICK JOHNSON. The shares are held by UCB Pharma SA (100%). It owns 41.1% of Farnia Biologics, 17.9% of ExeVir Bio and 4.4% of Grin Therapeutics, Inc. itself.
Directors
According to the 2025 annual accounts
since 2020
Jean-Luc FLEURIAL
Director
since 2017
since 2024
since 2023
Shareholders
100%
Participations
Establishments
Establishment units
Physical locations of this company
Researchdreef 60
1070 Anderlecht
Chemin du Foriest /
1420 Braine-l'Alleud
Active since 1 April 2014
Gaston Geenslaan 14
3001 Leuven
Active since 1 July 2021
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 10 companies are registered at this address.
All companies at this address →UCB Belgium
U C B
UCB PHARMA same network
€ 4.6 billion revenue · 2025
UCB Fipar same network
Fondation Emmanuel Janssen
+5 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0543.573.053
- VAT number
- BE 0543.573.053
- Registered office
- Researchdreef 60, 1070 Anderlecht
- Names & denominations
- UCB BIOPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 December 2013
- Peppol
- Active · Active since 12 Dec 2025
- Activities · NACE
Vervaardiging van geneesmiddelen
Speur- en ontwikkelingswerk op biotechnologisch gebied